The war on branded drugs: The Tipline for 30 July 2019
The waves of Actavis are still churning and they reached the shores of The Golden State yesterday. The state of California settled its pay-for-delay claims related to narcolepsy drug Provigil against Teva Pharmaceuticals. California attorney general Xavier Beccera said the resolution was the largest state-secured settlement related to reverse payments and the first to include injunctive relief barring similar agreements. Celgene, Mylan Laboratories and Sun Pharmaceuticals all settled claims they had illegally denied generic entry of branded medications on Friday. Speaking of Mylan, Pfizer announced plans to merge its generic drugs business with Mylan yesterday.
To read more
Subscribe to Global Competition Review
Subscribe and start reading now
Global Competition Review (GCR) is the complete source of news and analysis for competition practitioners. It keeps you up to speed with the issues and trends that matter, giving you the detail, and depth, you need to operate successfully.
Already have access? Login below
Copyright © Law Business ResearchCompany Number: 03281866 VAT: GB 160 7529 10